Enrolment of patients initiated in North America and Europe in Episurf Medical's IDE clinical trial

Episurf Medical (Nasdaq: EPIS B) today announces that the enrolment of patients has been initiated in the US and in Europe for the company's IDE clinical trial for the Episealer® knee implant. The clinical trial, EPIC-Knee Episealer® Knee System IDE Clinical Study, is a prospective, randomised, controlled multi-centre study with two years' follow-up of 180 subjects. The clinical trial is conducted at several clinics in the US, Canada, Germany, UK and Denmark.

"We aim at being the world leader in our emerging orthopaedic niche, where today, a considerable amount of patients are left without satisfactory treatments. This pivotal study study is the single largest and most important clinical trial that we are engaged in, given that the US market is, by far, the largest orthopaedic market in the world. If the clinical results generated for the Episealer® in Europe can be re-generated in the US, then we are facing a highly exciting future. Initiated patient enrolment in the IDE study is a milestone for us" says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.00 CEST on 23 June 2020.